Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why Mangoceuticals Stock Jumps 49% After H
Mangoceuticals (MGRX) shares rose more than 49% after hours after the company said it signed an MOU with Nuclea Energy to explore siting a nuclear test reactor at Utah’s San Rafael Energy Lab to support Nuclea’s Morpheus microreactor. Mangoceuticals and Nuclea have a July 30 business combination agreement, pending approvals. MGRX received a 180-day Nasdaq bid-price extension to Feb. 1, 2027.
How this was made
The 30-second read
Why it matters
The article provides two near-term supportive catalysts for MGRX: (1) an MOU progress update tied to siting a nuclear test reactor for Nuclea’s Morpheus microreactor, and (2) a 180-day Nasdaq extension to Feb. 1, 2027. However, it stresses the merger still requires stockholder and regulatory approval, keeping execution risk high.
Market read
Traders are likely repricing MGRX on merger optionality and Nasdaq listing risk reduction, but the approval overhang can drive sharp reversals.
What to watch
The Nasdaq $1 minimum bid extension reduces delisting pressure, but it does not remove dilution or liquidity risk typical of microcaps; technicals (RSI ~48) suggest no strong oversold/overbought signal to validate the magnitude of the move.
Background
Mangoceuticals (MGRX) entered a definitive business combination agreement with Nuclea to pursue a Nasdaq listing, while also working to regain Nasdaq $1 bid compliance.
Ticker impact
Mangoceuticals’ after-hours surge is tied to a definitive business combination agreement with Nuclea and an MOU progress update for the Morpheus microreactor.
Near-term volatility likely remains elevated until shareholder and regulatory approvals are secured; upside may fade if deal milestones slip.
The article cites a new MOU progress item and confirms the merger framework and Nasdaq extension, both supportive, but it also emphasizes the merger is still subject to approvals, limiting certainty.
Market effects
Highlights continued investor interest in advanced nuclear and microreactor commercialization pathways, though the immediate tradable catalyst is company-specific merger progress.
No clear regional market linkage beyond US Nasdaq listing mechanics.
Limited, as the nuclear siting and reactor development are early-stage and framed via an MOU.
Counterpoint
Because the update is an MOU and the merger remains subject to approvals, the 49% after-hours move may over-discount execution risk and regulatory timelines.
Key entities
- public_companyMangoceuticals
Microcap company whose stock jumped after hours on merger-related progress and a Nasdaq compliance extension.
- private_companyNuclea Energy
Ontario-based advanced nuclear startup developing the Morpheus microreactor; subject of the proposed business combination.
- facilityUtah San Rafael Energy Lab
Proposed site referenced in the MOU for a nuclear test reactor to advance Morpheus development.
